AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 6823418 — intervention group
Group type: EXPERIMENTAL
Intervention: Supplemented formula with taurine plus cholesterol
Number of subjects: 0
Study 6823418 — intervention group
Group type: COMPARATOR
Intervention: Unsupplemented formula
Number of subjects: 0
Study 6823418 — intervention group
Group type: COMPARATOR
Intervention: Human milk (185 mL/kg/d)
Number of subjects: 0
Study 6823418 — intervention group
Group type: EXPERIMENTAL
Intervention: Formula-fed groups
Number of subjects: 0
Study 2859362 — intervention group
Group type: EXPERIMENTAL
Intervention: High alpha-linolenic acid emulsion (3.0% alpha-linolenic acid)
Number of subjects: 20
Study 2859362 — intervention group
Group type: COMPARATOR
Intervention: Low alpha-linolenic acid emulsion (0.1% alpha-linolenic acid)
Number of subjects: 20
Study 29215189 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapagliflozin 10 mg
Number of subjects: 272
Study 29215189 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 272
Study 26720597 — intervention group
Group type: EXPERIMENTAL
Intervention: Weighted vaginal cones (WVC)
Number of subjects: 39
Study 26720597 — intervention group
Group type: COMPARATOR
Intervention: Tolterodine ER 4 mg/day for 8 weeks
Number of subjects: 39
Study 25085757 — intervention group
Group type: EXPERIMENTAL
Intervention: Autogenic training (AT) for 7 days after surgery
Number of subjects: 30
Study 25085757 — intervention group
Group type: COMPARATOR
Intervention: Control group (usual care)
Number of subjects: 30
Study 22424722 — intervention group
Group type: EXPERIMENTAL
Intervention: Nevirapine-based treatment after suppression with protease-inhibitor-based regimen
Number of subjects: 118
Study 22424722 — intervention group
Group type: COMPARATOR
Intervention: Protease-inhibitor-based treatment (ritonavir-boosted lopinavir)
Number of subjects: 118
Study 20121419 — intervention group
Group type: EXPERIMENTAL
Intervention: Nevirapine substitution due to efavirenz toxicity
Number of subjects: 0
Study 20121419 — intervention group
Group type: COMPARATOR
Intervention: Efavirenz therapy
Number of subjects: 0
Study 18155602 — intervention group
Group type: EXPERIMENTAL
Intervention: Tagger's hybrid technique
Number of subjects: 160
Study 18155602 — intervention group
Group type: COMPARATOR
Intervention: Lateral condensation
Number of subjects: 160
Study 18155602 — intervention group
Group type: COMPARATOR
Intervention: Touch 'n Heat + Ultrafil
Number of subjects: 160
Study 18155602 — intervention group
Group type: COMPARATOR
Intervention: Microseal
Number of subjects: 160
Study 18155602 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mm obturation
Number of subjects: 160
Study 18155602 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mm obturation
Number of subjects: 160
Study 16418463 — intervention group
Group type: EXPERIMENTAL
Intervention: Watchful waiting
Number of subjects: 720
Study 16418463 — intervention group
Group type: COMPARATOR
Intervention: Surgical repair
Number of subjects: 720
Study 14679990 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical approaches
Number of subjects: 0
Study 14679990 — intervention group
Group type: COMPARATOR
Intervention: Non-surgical approaches
Number of subjects: 0
Study 10875030 — intervention group
Group type: EXPERIMENTAL
Intervention: Dofetilide (15-min loading infusion of 4 g/kg followed by a 60-min maintenance infusion of 3.5 g/kg, total dose of 7.5 g/kg)
Number of subjects: 0
Study 10875030 — intervention group
Group type: COMPARATOR
Intervention: Placebo (single-blind infusion)
Number of subjects: 0
Study 8741938 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam (4 mg)
Number of subjects: 55
Study 8741938 — intervention group
Group type: EXPERIMENTAL
Intervention: Buspirone (5 mg)
Number of subjects: 55
Study 8741938 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam
Number of subjects: 55
Study 8741938 — intervention group
Group type: EXPERIMENTAL
Intervention: Buspirone
Number of subjects: 55
Study 8741938 — intervention group
Group type: EXPERIMENTAL
Intervention: Both diazepam and buspirone
Number of subjects: 55
Study 1423905 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitting (SIT) training in personal wheelchair and orthotic device
Number of subjects: 8
Study 1423905 — intervention group
Group type: COMPARATOR
Intervention: Semi-prone (SP) training on a prone board inclined 45 degrees
Number of subjects: 8
Study 1423905 — intervention group
Group type: EXPERIMENTAL
Intervention: Both SIT and SP training
Number of subjects: 8
Study 6145178 — intervention group
Group type: EXPERIMENTAL
Intervention: loprazolam 1 mg
Number of subjects: 12
Study 6145178 — intervention group
Group type: EXPERIMENTAL
Intervention: triazolam 0.5 mg
Number of subjects: 12
Study 6145178 — intervention group
Group type: EXPERIMENTAL
Intervention: withdrawal of either drug after 3 weeks
Number of subjects: 12
Study 6145178 — intervention group
Group type: COMPARATOR
Intervention: placebos
Number of subjects: 12
Study 31384902 — intervention group
Group type: EXPERIMENTAL
Intervention: Free gingival graft (FGG)
Number of subjects: 26
Study 31384902 — intervention group
Group type: COMPARATOR
Intervention: Subepithelial connective tissue graft (CTG)
Number of subjects: 26
Study 30398602 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled inorganic nitrite (46 mg 3 times a day for 1 week followed by 80 mg 3 times a day for 3 weeks)
Number of subjects: 105
Study 30398602 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 105
Study 30398602 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled inorganic nitrite
Number of subjects: 105
Study 26874155 — intervention group
Group type: EXPERIMENTAL
Intervention: Trainee screeners
Number of subjects: 1228
Study 26874155 — intervention group
Group type: COMPARATOR
Intervention: Ophthalmologist
Number of subjects: 1228
Study 23579053 — intervention group
Group type: EXPERIMENTAL
Intervention: Vertical strength (VS)
Number of subjects: 22
Study 23579053 — intervention group
Group type: EXPERIMENTAL
Intervention: Vertical and horizontal strength (VHS)
Number of subjects: 22
Study 22575544 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 μg I (as KI) daily throughout pregnancy
Number of subjects: 839
Study 22575544 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 839
Study 20211095 — intervention group
Group type: EXPERIMENTAL
Intervention: Piezosurgery (piezoelectric device)
Number of subjects: 100
Study 20211095 — intervention group
Group type: COMPARATOR
Intervention: Microdrill (traditional surgery)
Number of subjects: 100
Study 19092246 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose propofol (40 mg for <70 years, 30 mg for ≥70 years)
Number of subjects: 80
Study 19092246 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam (4 mg)
Number of subjects: 80
Study 19092246 — intervention group
Group type: COMPARATOR
Intervention: No sedation (control group)
Number of subjects: 80
Study 19092246 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose propofol
Number of subjects: 80
Study 19092246 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose propofol vs. Midazolam
Number of subjects: 80
Study 15593384 — intervention group
Group type: EXPERIMENTAL
Intervention: SELDI‐TOF‐MS protein fingerprinting with ANN algorithm
Number of subjects: 105
Study 12360457 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide 9 mg/day for 6 weeks
Number of subjects: 51
Study 12360457 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51
Study 10541047 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmon calcitonin (100 IU)
Number of subjects: 18
Study 10541047 — intervention group
Group type: COMPARATOR
Intervention: Aminophylline (500 mg)
Number of subjects: 18
Study 10541047 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmon calcitonin (100 IU/day subcutaneously for 3 days)
Number of subjects: 18
Study 8970501 — intervention group
Group type: EXPERIMENTAL
Intervention: Valproate (oral loading dosage)
Number of subjects: 0
Study 8970501 — intervention group
Group type: EXPERIMENTAL
Intervention: Valproate
Number of subjects: 0
Study 8970501 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbamazepine and lithium (combination treatment)
Number of subjects: 0
Study 8970501 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithium
Number of subjects: 0
Study 1856803 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral methotrexate (MTX)
Number of subjects: 123
Study 6433770 — intervention group
Group type: EXPERIMENTAL
Intervention: HB 419 (5 mg twice a day)
Number of subjects: 19
Study 6433770 — intervention group
Group type: EXPERIMENTAL
Intervention: HB 420 (3.5 mg twice a day)
Number of subjects: 19
Study 6433770 — intervention group
Group type: COMPARATOR
Intervention: Both HB 419 and HB 420
Number of subjects: 19
Study 30536837 — intervention group
Group type: EXPERIMENTAL
Intervention: R‐Pilot (VDW, Munich, Germany)
Number of subjects: 240
Study 30536837 — intervention group
Group type: EXPERIMENTAL
Intervention: ProGlider (Dentsply Sirona, Ballaigues, Switzerland)
Number of subjects: 240
Study 30536837 — intervention group
Group type: COMPARATOR
Intervention: Manual K‐files (Dentsply Sirona)
Number of subjects: 240
Study 30536837 — intervention group
Group type: EXPERIMENTAL
Intervention: R‐Pilot vs ProGlider
Number of subjects: 240
Study 26954726 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhalation of female emotional tears
Number of subjects: 0
Study 26954726 — intervention group
Group type: EXPERIMENTAL
Intervention: Sniffing tears
Number of subjects: 0
Study 26954726 — intervention group
Group type: EXPERIMENTAL
Intervention: Irritant tears
Number of subjects: 0
Study 26545199 — intervention group
Group type: EXPERIMENTAL
Intervention: 1,25(OH)2D3 (2 μg daily for 7 days)
Number of subjects: 42
Study 26545199 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study 24180161 — intervention group
Group type: EXPERIMENTAL
Intervention: Desflurane
Number of subjects: 0
Study 24180161 — intervention group
Group type: COMPARATOR
Intervention: Sevoflurane
Number of subjects: 0
Study 20427207 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasogastric tube application
Number of subjects: 202
Study 20427207 — intervention group
Group type: COMPARATOR
Intervention: No nasogastric tube application (control)
Number of subjects: 202
Study 19716512 — intervention group
Group type: EXPERIMENTAL
Intervention: MTA as an apical 5-mm filling (Group C)
Number of subjects: 51
Study 19716512 — intervention group
Group type: COMPARATOR
Intervention: Immediate post space preparation using heated instrument (Group A)
Number of subjects: 51
Study 19716512 — intervention group
Group type: COMPARATOR
Intervention: Delayed post space preparation after 1 week with Gates‐Glidden drills (Group B)
Number of subjects: 51
Study 17227325 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured Intensive Diabetes Education Programme (SIDEP)
Number of subjects: 547
Study 17227325 — intervention group
Group type: COMPARATOR
Intervention: Conventional glycaemic control without intensive education
Number of subjects: 547
Study 15236821 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychotropic analgesic nitrous oxide (PAN)
Number of subjects: 51
Study 15236821 — intervention group
Group type: COMPARATOR
Intervention: Benzodiazepines (BZs)
Number of subjects: 51
Study 11703244 — intervention group
Group type: EXPERIMENTAL
Intervention: Sedation with local anaesthesia
Number of subjects: 0
Study 11703244 — intervention group
Group type: EXPERIMENTAL
Intervention: General anaesthesia
Number of subjects: 0
Study 11703244 — intervention group
Group type: COMPARATOR
Intervention: Control group (learning curve for posturography)
Number of subjects: 0
Study 9273186 — intervention group
Group type: EXPERIMENTAL
Intervention: CEBI 140 trial: Combination of daily cisplatin (6 mg/m2 per day, total 144 mg/m2), vindesine (2.5 mg/m2 once a week, total 15 mg/m2), bifractionated radiotherapy (60 Gy/48 fractions/6 weeks) followed by two cycles of cisplatin (120 mg/m2) and three cycles of vindesine (6 mg/m2).
Number of subjects: 62
Study 9273186 — intervention group
Group type: EXPERIMENTAL
Intervention: CEBI 142 trial: Combination of cisplatin (100 mg/m2 at d1 and d24, total 200 mg/m2), vinblastine (4 mg/m2 at d1 and d24, total 8 mg/m2), 5-fluorouracil (1,000 mg/m2 from d1 to d3 and from d24 to d26, total 6,000 mg/m2), bifractionated radiotherapy (two series of 21 Gy/14 fractions/9 days, 11 days apart) followed by surgical excision.
Number of subjects: 62
Study 8224946 — intervention group
Group type: EXPERIMENTAL
Intervention: FASTPAC
Number of subjects: 98
Study 8224946 — intervention group
Group type: COMPARATOR
Intervention: Standard 4-2 double staircase strategy
Number of subjects: 98
Study 3319641 — intervention group
Group type: EXPERIMENTAL
Intervention: Atropine sulphate
Number of subjects: 20
Study 3319641 — intervention group
Group type: EXPERIMENTAL
Intervention: Bethanechol
Number of subjects: 20
Study 3319641 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostigmine
Number of subjects: 20
Study 3319641 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 30015203 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct anterior approach
Number of subjects: 33
Study 30015203 — intervention group
Group type: COMPARATOR
Intervention: Anterolateral approach
Number of subjects: 33
Study 26845098 — intervention group
Group type: EXPERIMENTAL
Intervention: 300,000 IU of cholecalciferol administered 4 days before surgery
Number of subjects: 25
Study 26845098 — intervention group
Group type: COMPARATOR
Intervention: Placebo administered during the first extraction (control group)
Number of subjects: 25
Study 25418907 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Number of subjects: 60
Study 25418907 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 23598861 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-guided training (n = 10) for 3 hours on 3 scenarios of increasing fidelity and difficulty
Number of subjects: 30
Study 23598861 — intervention group
Group type: EXPERIMENTAL
Intervention: Educator-guided training (n = 10) for 3 hours on 3 scenarios of increasing fidelity and difficulty
Number of subjects: 30
Study 23598861 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 10) with no previous simulator training
Number of subjects: 30
Study 21311960 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-based participatory research (CBPR) approach involving a community advisory committee (CAC) and a local women committee (LWC)
Number of subjects: 0
Study 21311960 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-based participatory research (CBPR) approach
Number of subjects: 0
Study 19583756 — intervention group
Group type: EXPERIMENTAL
Intervention: Five sessions of cognitive behavioural therapy (CBT) performed by dentists
Number of subjects: 55
Study 19583756 — intervention group
Group type: COMPARATOR
Intervention: One session of cognitive behavioural therapy (CBT) performed by dentists
Number of subjects: 55
Study 16960445 — intervention group
Group type: EXPERIMENTAL
Intervention: Statin therapy with bisoprolol
Number of subjects: 2647
Study 16960445 — intervention group
Group type: COMPARATOR
Intervention: Statin therapy with placebo
Number of subjects: 2647
Study 16960445 — intervention group
Group type: COMPARATOR
Intervention: No statin therapy with bisoprolol
Number of subjects: 2647
Study 16960445 — intervention group
Group type: COMPARATOR
Intervention: No statin therapy with placebo
Number of subjects: 2647
Study 16960445 — intervention group
Group type: EXPERIMENTAL
Intervention: Statin therapy (both with bisoprolol and placebo)
Number of subjects: 2647
Study 14979863 — intervention group
Group type: EXPERIMENTAL
Intervention: Expressive writing intervention (videotaped instructions)
Number of subjects: 373
Study 14979863 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard writing instructions
Number of subjects: 373
Study 14979863 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified set of instructions to extract meaning from the traumatic event
Number of subjects: 373
Study 14979863 — intervention group
Group type: COMPARATOR
Intervention: Inactive writing group
Number of subjects: 373
Study 14979863 — intervention group
Group type: COMPARATOR
Intervention: Attention control group
Number of subjects: 373
Study 11476119 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone (up to 10 mg/day)
Number of subjects: 62
Study 11476119 — intervention group
Group type: COMPARATOR
Intervention: Haloperidol (up to 20 mg/day)
Number of subjects: 62
Study 9707024 — intervention group
Group type: EXPERIMENTAL
Intervention: t(14;18) PCR
Number of subjects: 15
Study 9707024 — intervention group
Group type: EXPERIMENTAL
Intervention: CDRIII PCR
Number of subjects: 15
Study 7560704 — intervention group
Group type: EXPERIMENTAL
Intervention: In-home assessments
Number of subjects: 46
Study 7560704 — intervention group
Group type: COMPARATOR
Intervention: In-clinic assessments
Number of subjects: 46
Study 1976678 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine preparations
Number of subjects: 74
Study 1976678 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-medicated soap
Number of subjects: 74
Study 1976678 — intervention group
Group type: COMPARATOR
Intervention: Control (non-medicated soap)
Number of subjects: 74
Study 487693 — intervention group
Group type: EXPERIMENTAL
Intervention: D-amphetamine, 10 mg orally
Number of subjects: 0
Study 487693 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentazocine, 45 mg intramuscularly
Number of subjects: 0
Study 487693 — intervention group
Group type: COMPARATOR
Intervention: Nefopam (both doses)
Number of subjects: 0
Study 487693 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31862574 — intervention group
Group type: EXPERIMENTAL
Intervention: Imagery Rescripting (IR)
Number of subjects: 33
Study 31862574 — intervention group
Group type: EXPERIMENTAL
Intervention: Imaginal Exposure (IE)
Number of subjects: 33
Study 31862574 — intervention group
Group type: COMPARATOR
Intervention: Supportive Counselling (SC)
Number of subjects: 33
Study 31079746 — intervention group
Group type: EXPERIMENTAL
Intervention: Pecuniary information
Number of subjects: 0
Study 31079746 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-pecuniary information
Number of subjects: 0
Study 31079746 — intervention group
Group type: COMPARATOR
Intervention: No information treatment (control)
Number of subjects: 0
Study 27829323 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 ml of 6.7% maltodextrin solution (MALT)
Number of subjects: 9
Study 27829323 — intervention group
Group type: COMPARATOR
Intervention: Water (PLAC)
Number of subjects: 9
Study 27829323 — intervention group
Group type: EXPERIMENTAL
Intervention: MALT
Number of subjects: 9
Study 27829323 — intervention group
Group type: COMPARATOR
Intervention: PLAC
Number of subjects: 9
Study 26284153 — intervention group
Group type: EXPERIMENTAL
Intervention: Low ERI tertile (n=18)
Number of subjects: 53
Study 26284153 — intervention group
Group type: EXPERIMENTAL
Intervention: Medium ERI tertile (n=18)
Number of subjects: 53
Study 26284153 — intervention group
Group type: EXPERIMENTAL
Intervention: High ERI tertile (n=17)
Number of subjects: 53
Study 26284153 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall association
Number of subjects: 53
Study 25135598 — intervention group
Group type: EXPERIMENTAL
Intervention: Bright light therapy (controlled lighting: lights on at 06:30 and off at 22:30, blue-enriched light in the morning, red-enriched light in the afternoon/evening)
Number of subjects: 12
Study 25135598 — intervention group
Group type: COMPARATOR
Intervention: Standard lighting (control group)
Number of subjects: 12
Study 25135598 — intervention group
Group type: EXPERIMENTAL
Intervention: Bright light therapy
Number of subjects: 12
Study 24252551 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative pressure wound therapy (V.A.C.®)
Number of subjects: 0
Study 24252551 — intervention group
Group type: COMPARATOR
Intervention: Standard conventional wound therapy
Number of subjects: 0
Study 22453669 — intervention group
Group type: EXPERIMENTAL
Intervention: Solifenacin
Number of subjects: 750
Study 22453669 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 750
Study 18344693 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise participation
Number of subjects: 53
Study 18344693 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise session attendance
Number of subjects: 53
Study 18344693 — intervention group
Group type: EXPERIMENTAL
Intervention: Changes in tension and physical self-concept
Number of subjects: 53
Study 18344693 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise
Number of subjects: 53
Study 18344693 — intervention group
Group type: EXPERIMENTAL
Intervention: Improvement in depression
Number of subjects: 53
Study 17146380 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg amitriptyline at bedtime
Number of subjects: 28
Study 17146380 — intervention group
Group type: COMPARATOR
Intervention: 10 to 100 mg/5 mL, 10 mL codeine/guaifenesin every 6 hours standing dose while awake
Number of subjects: 28
Study 17146380 — intervention group
Group type: EXPERIMENTAL
Intervention: amitriptyline
Number of subjects: 28
Study 14616886 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocortisone
Number of subjects: 10
Study 14616886 — intervention group
Group type: EXPERIMENTAL
Intervention: Cortisone acetate
Number of subjects: 10
Study 14616886 — intervention group
Group type: COMPARATOR
Intervention: Control population (normal subjects)
Number of subjects: 10
Study 10881245 — intervention group
Group type: EXPERIMENTAL
Intervention: Blind Braille readers
Number of subjects: 30
Study 10881245 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported dominant reading finger in blind subjects
Number of subjects: 30
Study 10881245 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-Braille reading fingers in blind subjects
Number of subjects: 30
Study 10881245 — intervention group
Group type: COMPARATOR
Intervention: Sighted control subjects
Number of subjects: 30
Study 9646667 — intervention group
Group type: EXPERIMENTAL
Intervention: Desflurane (3 +/- 1.5%)
Number of subjects: 30
Study 9646667 — intervention group
Group type: COMPARATOR
Intervention: Isoflurane (0.6 +/- 0.3%)
Number of subjects: 30
Study 7876502 — intervention group
Group type: EXPERIMENTAL
Intervention: Early active short arc motion initiated between the second day and the eleventh day after repair
Number of subjects: 0
Study 7876502 — intervention group
Group type: COMPARATOR
Intervention: 3‐6 weeks of continuous immobilization followed by a vigorous standard rehabilitation program
Number of subjects: 0
Study 2830407 — intervention group
Group type: EXPERIMENTAL
Intervention: RA‐233 plus chemotherapy
Number of subjects: 719
Study 2830407 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy alone
Number of subjects: 719
Study 31453490 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolotherapy injections (ultrasound-guided, 5 points, 3 times every 21 days)
Number of subjects: 60